RB1 and adenocarcinoma: This is almost certain given that, even in switched SCLC, Rb1 was lost in 100% of cases [88] and was the substrate of the trial (NCT03567642) for the upfront use of TKI and platinum/etoposide-based chemotherapy in adenocarcinoma carrying the triple mutation EGFR-Rb-p53.